Revvity, Inc. announced the development of the T-SPOT A201, a next-generation high-throughput automated platform designed to support the performance advantages of T-SPOT.TB testing for large-volume clinical labs, enabling a reliable, accurate solution for latent tuberculosis (TB) detection.

Building on the success of the Auto-Pure 2400 liquid handler, the T-SPOT A201 platform is engineered to meet the throughput requirements of large-scale testing environments, strengthening the Company’s automation portfolio and its ability to support labs across a range of throughput needs. It can process up to 384 samples per instrument in an 8-hour shift, with 45 seconds per sample of hands-on time – the lowest of any T-SPOT automation solution. The platform aims to ensure that these labs benefit from the scalability and workflow advantages associated with automated T-SPOT.TB testing.

Additional studies on the performance of the Company’s automation solutions will be released in the coming months. The T-SPOT A201 platform is currently under development and targeted for launch in the second half of 2027, subject to regulatory approval.

Revvity’s Euroimmun business will be showcasing its latest automation solutions at the ADLM 2026 conference in Anaheim, California from July 26 – 30 at booth #1411, with a T-SPOT.TB breakfast workshop on July 28. To register, please visit the website here.

The T-SPOT A201 platform is currently under development and not yet available for sale.

Visit Revvity for more information